Acceleron to Host Virtual Research and Development (R&D) Day on June 22, 2021
08 Giugno 2021 - 1:00PM
Business Wire
- Event to be webcast on Tuesday, June 22 at
8:00 a.m. EDT -
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical
company in the discovery, development, and commercialization of
TGF-beta superfamily therapeutics to treat serious and rare
diseases, today announced it will host a Virtual R&D Day for
analysts and investors on June 22, 2021. The virtual event will
take place from 8:00 a.m. to approximately 11:00 a.m. EDT.
Members of the Acceleron leadership team, along with external
experts, will review the Company’s numerous ongoing and planned
trials in rare pulmonary diseases, and highlight Acceleron’s vision
and strategy for long-term growth.
Guest Presenters:
- Mardi Gomberg-Maitland1, M.D., MSc, Professor of
Medicine and Director of the George Washington University Hospital
Pulmonary Hypertension Program
- Marc Humbert1, M.D., Ph.D., Professor of Medicine and Director
of the French Pulmonary Hypertension Reference Center at the
Université Paris-Saclay
- Vallerie McLaughlin1, M.D., Professor of Medicine and Director
of the Pulmonary Hypertension Program at the University of
Michigan
A live webcast of the presentation and question and answer
sessions will be accessible under “Events & Presentations” in
the Investors & Media page of the Company’s website at
www.acceleronpharma.com. To register for the event, please visit
the R&D Day 2021 Registration Site.
An archived recording of the webcast will be available for
replay on the Company’s website beginning approximately two hours
after the event.
1Drs. Gomberg, Humbert, and McLaughlin are investigators in
multiple ongoing and planned Acceleron-sponsored clinical trials
and are paid consultants to Acceleron.
About Acceleron
Acceleron is a biopharmaceutical company dedicated to the
discovery, development, and commercialization of therapeutics to
treat serious and rare diseases. Acceleron’s leadership in the
understanding of TGF-beta superfamily biology and protein
engineering generates innovative compounds that engage the body's
ability to regulate cellular growth and repair.
Acceleron focuses its research, development, and
commercialization efforts in pulmonary and hematologic diseases. In
pulmonary, Acceleron is developing sotatercept for the treatment of
pulmonary arterial hypertension (PAH), having reported positive
topline results of the PULSAR Phase 2 trial. The Company is
currently planning multiple Phase 3 trials with the potential to
support its long-term vision of establishing sotatercept as a
backbone therapy for patients with PAH at all stages of the
disease. Acceleron is also investigating the potential of its
early-stage pulmonary candidate, ACE-1334, which it plans to
advance into a Phase 1b/Phase 2 trial in systemic
sclerosis-associated interstitial lung disease (SSc-ILD) this
year.
In hematology, REBLOZYL® (luspatercept-aamt) is the first and
only erythroid maturation agent approved in the United States,
Europe, and Canada for the treatment of anemia in certain blood
disorders. REBLOZYL is part of a global collaboration partnership
with Bristol Myers Squibb. The Companies co-promote REBLOZYL in the
United States and are also developing luspatercept for the
treatment of anemia in patient populations of myelodysplastic
syndromes, beta-thalassemia, and myelofibrosis.
For more information, please visit www.acceleronpharma.com.
Follow Acceleron on Social Media: @AcceleronPharma and
LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210608005186/en/
Acceleron Pharma Inc.
Investors: Jamie Bernard, IRC, 617-301-9650 Associate Director,
Investor Relations
Media: Matt Fearer, 617-301-9557 Senior Director, Corporate
Communications
Grafico Azioni Acceleron Pharma (NASDAQ:XLRN)
Storico
Da Gen 2025 a Feb 2025
Grafico Azioni Acceleron Pharma (NASDAQ:XLRN)
Storico
Da Feb 2024 a Feb 2025
